Royalty Pharma plc stirs market activities with various strategic moves.
Major institutional owners have made changes to their stock positions in the company: Plato Investment Management, Bank of New York Mellon Corp, Metis Global Partners, Principal Financial Group and others have trimmed their positions, while Truist Financial Corp, SBI Securities, New South Capital Management, Handelsbanken Fonder AB and others have expanded theirs.
Royalty Pharma missed Q4 revenue estimates, however, their earnings seem to beat expectations. Furthermore, the company hit a 52-week high amid growth, later hitting a 52-week low due to market shifts.
Jim Cramer, a notable market commentator, expressed disappointment in the stock's performance. The company unveiled a $
3 billion buyback plan and expects $1.6 billion savings from a
manager acquisition. Similarly, Royalty Pharma showcased record deals and peak pipeline royalties while it plans to back a
Revolutionary Lupus Treatment with a $250M deal. Despite some negative sentiments,
analysts predict a 31.15% upside in the near term.
Royalty Pharma Stocks News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 09:29:57 GMT -
Rating 5
- Innovation -3
- Information 7
- Rumor -7
